2,3-O-cyclohexylidene-D-glycerohydroximoyl chloride | 771479-11-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,3-O-cyclohexylidene-D-glycerohydroximoyl chloride
• 英文别名: (R)-N-hydroxy-1,4-dioxaspiro[4.5]decane-2-carbimidoyl chloride；(3R)-N-hydroxy-1,4-dioxaspiro[4.5]decane-3-carboximidoyl chloride
• CAS: 771479-11-9
• 化学式: C₉H₁₄ClNO₃
• 分子量: 219.668
• InChiKey: FHWDQLCHWMIDCB-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  51
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,3-O-cyclohexylidene-D-glycerohydroximoyl chloride 在 三乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 47.0h， 生成 (1'S)-3-(1',2'-cylohexylidenedioxyethyl)-2-methyl-4,5-dihydro-1,2-oxazolium tetrafluoroborate
  参考文献：
  名称：

  Isoxazolinium Salts in Asymmetric Synthesis. 1. Stereoselective Reduction Induced by a 3’-Alkoxy Stereocentre. A New Approach to Polyfunctionalized β-Amino Acids* [1, 2]

  摘要：

  摘要：介绍了一种新的光学活性N-甲基氨基酸的方法，该方法依赖于具有二氧乙基侧链的N-甲基异噁唑盐的立体选择性还原。与相应的异噁唑烷相比，系统研究了还原步骤的对映选择性。通过NaBH₃(OAc)的两步转化和随后的催化氢化以及一锅法催化氢化的还原，得到了受保护的齐式-N-甲基氨基戊三醇的高（95:5和87:13）对映体比。通过氧化来拓展羟乙基侧链，得到β-N-甲基氨基酸37，展示了该策略的潜力。

  DOI：

  10.1515/znb-2004-0414
• 作为产物：
  描述：

  2,3-O-cyclohexylidene-D-glyceraldoxime 在 盐酸 、 N-氯代丁二酰亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以99%的产率得到2,3-O-cyclohexylidene-D-glycerohydroximoyl chloride
  参考文献：
  名称：

  Novel Isoxazolinyl Spiropyrrolidinediones: 1,3-Dipolar Cycloaddition of 1-Benzyl-3,3-dimethyl-5-methylenepyrrolidin-2,4-dione

  摘要：

  提出了一种简单且高效的方法，用于从酮酸酯合成异噁唑啉基螺吡咯烷二酮。

  DOI：

  10.1055/s-0030-1259926

文献信息

• Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
  申请人：Aicher Thomas Daniel

  公开号：US20100204240A1

  公开（公告）日：2010-08-12

  Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供的化合物式(I)如下：其中R2、R3、R13、L和D2如规范中所定义，这些化合物可用于治疗和/或预防由于葡萄糖激酶活性不足引起或可以通过激活葡萄糖激酶治疗的疾病或紊乱，包括但不限于糖尿病、糖耐量受损、IFG（空腹血糖受损）和IFG（空腹高血糖），以及本文所讨论的其他疾病和紊乱。
• Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
  申请人：AICHER Thomas Daniel

  公开号：US20120277242A1

  公开（公告）日：2012-11-01

  Provided are compounds of Formula (I): wherein R 2 , R 3 , R 13 , L and D 2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  本发明提供了式(I)的化合物：其中R2、R3、R13、L和D2如规范中所定义，它们在治疗和/或预防由葡萄糖激酶活性不足介导的疾病或疾病中有用，或者可以通过激活葡萄糖激酶来治疗，包括但不限于糖尿病、糖耐量受损、IFG（空腹血糖受损）和IFG（空腹高血糖），以及其他疾病和疾病，如在此处所讨论的。
• Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
  申请人：Array BioPharma, Inc.

  公开号：US08212045B2

  公开（公告）日：2012-07-03

  Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供的化合物式(I)如下：其中R2、R3、R13、L和D2如规范中所定义，可用于治疗和/或预防由于葡萄糖激酶活性不足而介导的疾病或疾病，或可通过激活葡萄糖激酶来治疗，包括但不限于糖尿病、糖耐量受损、空腹血糖受损(IFG)和空腹高血糖(IFG)，以及其他在此处讨论的疾病和紊乱。
• Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
  申请人：Aicher Thomas Daniel

  公开号：US08853409B2

  公开（公告）日：2014-10-07

  Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.

  提供的是公式（I）化合物：其中R2，R3，R13，L和D2如规范中所定义，这些化合物对于治疗和/或预防由葡萄糖激酶活性不足引起或可以通过激活葡萄糖激酶来治疗的疾病或疾病具有用处，包括但不限于糖尿病，糖耐量受损，IFG（空腹血糖受损）和IFG（空腹高血糖），以及其他疾病和疾病，如本文所述。
• Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives
  申请人：Array BioPharma Inc.

  公开号：US09079890B2

  公开（公告）日：2015-07-14

  Provided are intermediates having the formulas wherein R2, R3, and L are as defined in the specification, which are useful in the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives.

  提供的中间体具有以下公式，其中R2，R3和L如说明书所定义，这些中间体在制备吡啶-2-基氨基-1,2,4-噻二唑衍生物时是有用的。